Business
Voyager Therapeutics Appoints Catherine J. Mackey, Ph.D. to its Board of Directors
CAMBRIDGE, Mass., July 28, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy company developing life-changing treatments and
About this update from Voyager Therapeutics, Inc.
[{"type":"text","content":"CAMBRIDGE, Mass., July 28, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy company developing life-changing treatments and next-generation adeno-associated virus (AAV) capsids, today announced the appointment of Catherine J. Mackey, Ph.D. to its Board of Directors. Dr. Mackey is a seasoned life science executive with more than thirty years of operational experience highlighted by her tenure as Senior Vice President, Global Research & Development, for Pfizer, Inc. “I am delighted to welcome Catherine to our Board at this pivotal time in Voyager’s evolution,” said Al Sandrock, M.D., Ph.D., chief executive officer of Voyager. “Her outstanding track record of R&D success coupled with her vast expertise in strategic collaborations with industry partners will be invaluable to Voyager as we advance our pipeline and maximize our TRACERTM capsid discovery platform.” “Voyager is uniquely positioned to help fulfill the vast potential of AAV gene therapy and drive new therapeutic breakthroughs, both with its pipeline and through collaborations with pharma leaders,” remarked Dr. Mackey. “I am pleased to join the Board and look forward to working with Voyager’s leadership team and my fellow Board members to help execute on the company's commitment to driving scientific advancements with the promise of changing the landscape of AAV gene therapy.” During her tenure at Pfizer, Dr. Mackey led La Jolla Labs where she oversaw more than 1,000 staff on a one-million square foot campus, delivering a steady-state pipeline of more than two dozen development compounds. Prior to her role at Pfizer La Jolla, Dr. Mackey led Strategic Alliances at its R&D headquarters, where she gained extensive experience with both corporate and academic partnerships in the U.S. and global markets. Additionally, she led Pfizer’s U.S. R&D efforts in Genomic and Proteomic Sciences, which included biomarker and pharmacogenomics research. Dr. Mackey currently serves as a board member for Cour Pharmaceuticals, Avid Bioservices, and IDEAYA Biosciences. Dr. Mackey, who will join the Voyager’s Board effective on August 15, has been designated as a Class I director with a term ending as of the 2025 annual meeting of Voyager shareholders. Dr. Mackey has also been appointed to the Board’s Audit Committee and Science and Technology Committee. About th...